Rtss-voice: towards a unified system to classify treatments for muscle tension dysphonia

Active Project Grant Awarded Last action

Award ID
R01DC020247
Recipient
Awarding agency
Obligated
$4,466,036

Award facts

Completion date 86% complete
Funding
  • $3,972,222.00 Federal
  • $493,814.00 Non-federal
Place of performance
Boston, MA 02114, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Systematically improving upon current voice therapy outcomes is problematic as the specific clinician actions (i.e., ingredients) responsible for improved patient functioning (i.e., targets) are unknown. For example, comparative effectiveness research (CER) can show that therapy a works better than therapy b on global outcome x. But why did therapy a provide better outcomes? Why did some patients in therapy b significantly improve with the "worse" program; and some patients in therapy a remain unchanged with the "better" program? A theory-based system is needed to scientifically identify a program's ingredients associated with improved outcomes across patients. And standard labels are needed to make the identified active ingredients generalizable across therapy programs. Therefore, this project will use a theory-driven framework for describing the ingredients/targets of rehabilitation treatments-called the rehabilitation treatment specification system (rtss)-and standard voice-specific terminology/definitions-called the rtss-voice- to standardly describe (aim 1) and compare (aim 2) variations in treatment across 9 well-known and diverse voice therapies. Also, we will create/test an implementation toolkit to facilitate rtss-voice adoption in clinical care across 5 voice centers (aim 3). IT is hypothesized that the rtss and rtss-voice will characterize all therapies without needing revisions (aim 1) and identify ingredients/targets that are unique to one therapy and/or common across multiple therapies (AIM2). And since the rtss-voice will help clinicians think about their treatment more specifically and in relation to 9 evidence-based therapies, we hypothesize adoption will be associated with improved outcomes at all 5 voice centers. The resulting list of mutually exclusive ingredient/targets across therapy programs will obviously improve the state of CER by enabling the identification/comparison of active ingredients across therapy programs; instead of the current practice of studying/comparing entire programs. Clinical adoption will result in large datasets with standard ingredients linked to outcomes, which will facilitate innovative hypotheses and interpretable datamining/machine learning to realistically improve voice therapy effectiveness. This work is likely to generalize to other centers due to the involvement of >20 influential clinicians and the implementation toolkit.

Transactions

Action Federal Non-federal Date
Amendment $557,249 $0
Amendment $582,618 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $465,543 $0
Amendment $465,543 $0
Amendment $419,827 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $493,814 $0
Amendment $493,814 $493,814
Original award $493,814 $0
Show all 21

Subawards

Subrecipient Amount Awarded
The MGH Institute Of Health Professions, Inc. Dr. Lyons is a rehabilitation scientist with expertise in intervention development and implementation science. She is principal investigator of an R01 grant… $33,837
New York University Primary muscle tension dysphonia (pMTD) is the most commonly seen behaviorally based voice disorder and voice therapy is the primary treatment option.… $40,121
University Of Wisconsin System Primary muscle tension dysphonia (pMTD) is the most commonly see behaviorally based voice disorder and voice therapy is the primary treatment option. Standard… $42,871
Emory University •Statement of work Primary muscle tension dysphonia (pMTD) is the most commonly seen behaviorally based voice disorder and voice therapy is the primary… $101,415
University Of Utah Primary muscle tension dysphonia (pMTD) is the most commonly seen behaviorally based voice disorder and voice therapy is the primary treatment option.… $107,848

Quick answers

Who received award R01DC020247?

R01DC020247 was awarded to The General Hospital Corporation by National Institute on Deafness and Other Communincation Disorders (National Institutes of Health) on September 16, 2022.

How much is award R01DC020247 worth?

$4,466,036 has been obligated on R01DC020247: $3,972,222 in federal funding and $493,814 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login